How Long Does It Take for Dysport to Kick In? Where the Timeline Stops Scaling

For FDA-labeled glabellar (frown) lines, Dysport may begin to kick in within 24 hours, while the median onset is 2 to 3 days, according to the systematic review by Nestor and colleagues; the U.S. prescribing information reports efficacy at Day 14 and uses Day 30 for its formal success endpoint. In practical terms, look for an early change during Days 2 to 4 and compare movement again around Day 14. Day 30 is the trial’s measurement date; most onset occurs much earlier.

How quickly should Dysport work, day by day?

A Dysport timeline has four clocks. Onset is the first noticed change; a settled result has had time to develop. A trial response depends on its scoring rule. Duration ends when enough muscle activity returns to matter. Mixing these clocks makes accurate numbers sound contradictory.

The 2020 systematic review by Nestor and colleagues examined 42 studies of abobotulinumtoxinA (Dysport). Using reported means or medians, at least 50% response, or a significant difference from placebo or baseline, onset appeared most often within 2 to 3 days in seven studies and as early as 24 hours in two. All 24 studies assessing the first week found some response at their first assessment.

Here is the useful day-by-day reading of those data:

• Day 0: Raised spots, redness, or swelling can alter appearance immediately. An injection-site effect does not show reduced muscle activity.
• Day 1: Baumann and colleagues’ pooled phase 3 analysis found 19.7% of Dysport-treated participants reported onset by Day 1; individual-trial response ranged from 13.4% to 32.5%.
• Days 2 to 4: This is the median-onset window. The phase 3 analysis found a 2-to-4-day median; Dysport’s U.S. patient site reports 2 days in GL-3 and 3 days in GL-1 and GL-2.
• Day 7: A growing difference between maximum frown and baseline is more informative than a still photograph at rest. Static creases may remain after muscle contraction has weakened because a neuromodulator changes movement; it does not refill an etched line.
• Day 14: In GL-1, investigators rated 90% of recipients as having no or mild lines at maximum frown; subjects rated 77%. These one-rater results differ from the stricter Day 30 composite.

I once got the inspection order wrong in my own field. I covered lifting builder gel instead of removing it; an infection followed, and it was my call. That is why I trust matched evidence over a polished surface. For Dysport, compare the same expression, angle, distance, and lighting with baseline. A relaxed selfie can hide active frown movement without measuring treatment.

What did the FDA-labeled glabellar-line trials actually measure?

The current DailyMed Dysport prescribing information specifies 50 Dysport Units divided among five intramuscular sites: 10 Units per site, with two injections in each corrugator and one in the procerus. The indication covers moderate to severe glabellar lines associated with those muscles in adults younger than 65.

Three pivotal placebo-controlled studies enrolled healthy adults aged 19 to 75 with at least moderate lines at maximum frown. Day 30 success required both investigator and subject to rate them none or mild, with at least a two-grade improvement. Composite response was 55% in GL-1, 52% in GL-2, and 60% in GL-3; placebo achieved 0% each time.

Those percentages sit below the 90% investigator rating at Day 14 because Day 30 demanded agreement between subject and investigator plus two grades of improvement. Moving from “severe” to “mild” could qualify; moving from “moderate” to “mild” could look improved yet miss the rule. Endpoint wording controls the number.

The strongest argument against Day 30 is that it is late for an onset question. True: half of patients in onset analyses noticed a response by Day 2 or 3. Day 30 compares trials under a strict definition; Day 14 is a practical checkpoint for discussing symmetry, residual movement, and expectations.

Follow-up sets a boundary around duration claims. GL-1 followed 158 previously untreated subjects for 180 days; GL-3 followed 300 for 150 days. GL-2 allowed up to four treatments, and trial completers could enter a two-year open-label study. Five-month observation has direct coverage, though individual duration varied.

The trials enrolled ages 19 to 75, and the pooled safety table covered 398 Dysport recipients across that range, yet the indication is for adults under 65. Only eight participants aged 65 or older were randomized: four received Dysport, and none met Day 30 composite success. That sample cannot establish response in older adults.

Where does the glabellar timeline stop scaling?

The 2-to-3-day median belongs to a product, dose pattern, muscle group, and outcome definition. It becomes less certain each time one of those changes. This table marks the boundary.

| Evidence setting | What was studied | Timing you can quote | Where scaling fails | |---|---|---|---| | FDA-labeled Dysport glabellar treatment | 50 Dysport Units across five corrugator/procerus sites | Some response within 24 hours; median onset 2 to 3 days across the literature | It does not establish a forehead-only or masseter timeline | | Dysport versus Botox comparisons | Different labeled units, often at five glabellar sites; study methods vary | One 2025 trial detected faster Day 3 strain reduction with Dysport, while another randomized trial found nearly identical female onset estimates | Brand units cannot be converted, and one study’s ratio cannot become a dosing rule | | Dysport in the forehead or masseter | U.S. use outside the Dysport cosmetic indication | Small upper-face studies report early changes, but there is no FDA-labeled Dysport onset or dose for either area | Muscle size, treatment goal, placement, and endpoint all change |

DailyMed states that Dysport potency Units are specific to its preparation and assay. They cannot be compared with or converted into the Units of another botulinum toxin product. Botox Cosmetic carries the same warning for its own Units. A quote for 50 Dysport Units and one for 20 Botox Units therefore describe two product-specific regimens, rather than a 2.5-to-1 exchange rate a patient can safely calculate.

Around 2022, I used to advise readers to compare the unit count on cosmetic quotes as a rough value check. I stopped. The label language made the flaw plain: unit totals lose meaning when product, indication, injection map, and concentration disappear. My cure logs for nail enhancements work the same way. “Sixty seconds” proves little without the lamp, gel, layer, and manufacturer’s cure specification attached to it.

Forehead treatment exposes the confusion neatly. The FDA label for Botox Cosmetic specifies 20 Botox Units in five frontalis sites together with 20 Botox Units in five glabellar sites, for 40 Units total. The Dysport label supplies no cosmetic forehead regimen. FDA guidance says clinicians may prescribe an approved drug for an unapproved use when medically appropriate, but the agency has not determined safety and effectiveness for that unapproved use.

Masseter treatment stretches the inference further. The desired outcome may be reduced clenching force, a softer masseter bulge during contraction, or gradual lower-face slimming. Those are different endpoints, and the Dysport U.S. label supplies neither a cosmetic masseter dose nor a masseter-onset day. A glabellar Day 3 figure cannot answer when a jaw-contour change will appear.

Is Dysport actually faster than Botox?

Dysport is not guaranteed to act faster than Botox for every patient. The separate product sources are close: Dysport literature most often places onset at 2 to 3 days, while the January 2026 DailyMed Botox Cosmetic label says chemical denervation typically begins 1 to 2 days after injection and increases during the first week. Separate labels do not create a head-to-head result.

A 2025 JAMA Dermatology randomized trial by Lemdani and colleagues gives better comparative evidence. It assigned 143 women aged 30 to 65 to one of four toxins at their labeled glabellar doses, including 50 Dysport Units and 20 Botox Units. Three-dimensional imaging found a 67.4% median reduction in dynamic strain with Dysport at Day 3 versus 48.0% with Botox. Dysport reached 85.3% of its own maximum treatment efficacy on Day 3 and maintained a similar 80.1% at Day 30.

That finding supports faster early strain reduction under one protocol. Its limits matter: the study included only women, missed some later visits, and was funded by Evolus, the maker of a third product in the comparison. A 2013 randomized trial of 180 adults used 63 abobotulinumtoxinA Units and 21 onabotulinumtoxinA Units; among women, estimated onset was 5.32 days and 5.29 days, respectively. Different definitions and ratios produced a different answer.

My position is narrower than the marketing claim. Dysport has credible evidence of rapid onset and may be faster under some glabellar protocols. No comparative study can promise which product will appear first on one particular face. Baseline muscle activity, sex, dose selection, placement, and the definition of “working” remain inside that uncertainty.

On which day does Dysport peak?

There is no single FDA-labeled “peak day” for cosmetic Dysport. The label reports GL-1 results at Day 14 and defines the pivotal composite endpoint at Day 30. The 2025 strain study found Dysport’s maximum treatment efficacy at Day 3, with a similar effect at Day 30, while an upper-face study summarized in the Nestor review observed peak wrinkle improvement around Day 7.

For planning, treat Day 14 as a review point rather than a biological deadline. By then, a Days 2-to-4 starter should have enough visible development for the injector to assess movement and symmetry. Waiting for that review avoids treating a normal early asymmetry as a final result. Dose changes remain the prescriber’s decision.

How long does Dysport last, and when can it be repeated?

The DailyMed label says the clinical effect on glabellar lines may last up to four months and directs that retreatment occur no more frequently than every three months. “Up to” describes an observed upper span, while the three-month rule is the minimum labeled interval between treatments. They answer different questions.

Dysport’s patient website says results may last up to five months. Its footnote ties that claim to a post-hoc analysis of at least a one-grade improvement in GL-1 and GL-3, studies that followed participants for at least 150 days. The broader Nestor review found duration reported most often at four months across 18 studies, with four studies showing efficacy at five months and three at six months or later. A faint one-grade response at Month 5 is a lower bar than the strict Day 30 composite success endpoint.

Plan the next assessment around return of meaningful movement and the labeled three-month minimum, not a calendar promise copied from someone else’s result. Earlier top-ups can change the exposure and the symmetry before the first treatment has been fully assessed.

How can you tell whether Dysport is working?

Test the movement that was treated. For glabellar lines, use maximum frown because that is the expression in the pivotal studies. Compare it with a baseline photograph made before injection, keeping camera distance, angle, lighting, and facial effort as consistent as possible. Look for reduced corrugator and procerus contraction; judge a deep resting crease separately.

A useful treatment record names the exact product, indication, total dose, injection sites, treatment date, and planned follow-up date. “Tox in forehead, 20 units” is too incomplete to resolve whether the product was Dysport or Botox, whether the glabella was included, or which evidence applies. Lot number and dilution belong in the clinical record as well.

I cannot personally vouch for injection placement, dose selection, or what a particular face should receive; I do not inject patients. I can vouch for the cost of weak service records. Prep photographs, cure logs, soak-off timing, and e-file bit wear let me reconstruct a nail failure. The equivalent Dysport record should let the prescriber reconstruct exactly what was injected before anyone explains a slow or uneven result.

Which symptoms require medical help instead of more waiting?

A lack of visible change on Day 1 is compatible with the normal Dysport onset window. Trouble swallowing, speaking, or breathing belongs to a different clock. The Dysport boxed warning says symptoms consistent with spread of toxin effect have been reported hours to weeks after injection and can include generalized weakness, double or blurred vision, drooping eyelids, voice or speech changes, urinary incontinence, and breathing difficulty. Swallowing and breathing problems can be life-threatening; seek immediate medical care for those symptoms.

The pooled glabellar trials provide context for more common reported events. Any adverse reaction occurred in 48% of Dysport recipients and 33% of placebo recipients; headache occurred in 9% versus 5%, injection-site pain in 3% versus 2%, and eyelid ptosis in 2% versus under 1%. Percentages describe trial groups. They cannot determine the cause of a new symptom in one person.

Frequently asked questions

Is Dysport faster acting than Botox?

Sometimes, but no patient can be promised that result. Dysport studies most often report onset in 2 to 3 days; the Botox Cosmetic label says denervation begins in 1 to 2 days. A 2025 randomized glabellar trial found faster Day 3 strain reduction with Dysport, while another randomized study found nearly identical female onset estimates.

On which day does Dysport peak?

The U.S. Dysport label does not define one peak day. Its glabellar trial reports include Day 14 results and a Day 30 primary endpoint. A 2025 imaging trial found Dysport’s maximum measured efficacy at Day 3 with similar Day 30 efficacy. A Day 14 review lets the prescriber judge the developed visible result.

How can I tell whether Dysport is working?

Recreate the treated expression, usually maximum frown for glabellar lines, and compare it with a pre-injection photo using the same angle, distance, lighting, and effort. Reduced movement between the brows is stronger evidence than a relaxed selfie. A deep line at rest may remain even when the injected muscles are contracting less.

Is 20 units of Dysport enough for the forehead?

There is no FDA-labeled Dysport dose for cosmetic forehead treatment, so 20 Dysport Units cannot be judged in isolation. Do not borrow the Botox Cosmetic label’s 20-unit frontalis dose: Botox Units cannot be converted to Dysport Units, and that Botox regimen also includes 20 Units in the glabella. Ask for the product-specific injection map.

How long does Dysport take to work on the forehead?

Cosmetic forehead use is outside the U.S. Dysport label, so there is no FDA-labeled forehead onset. Small upper-face studies have detected changes within the first several days, but their doses and endpoints vary. Use the injector’s documented plan and an approximately Day 14 comparison instead of applying the glabellar median as a guarantee.

How long does Dysport take to work compared with Botox?

Dysport’s median reported onset is 2 to 3 days; the Botox Cosmetic label describes denervation beginning in 1 to 2 days and increasing during the first week. Head-to-head findings vary with dose, sex, facial area, and outcome measure. Dysport may appear faster in some protocols, but neither timeline predicts every patient.

What indication, injection sites, and follow-up date did my injector document?

Your record should identify Dysport by name, state the treated indication, map each injection site, list the total and per-site Dysport Units, and give the treatment and follow-up dates. For labeled glabellar treatment, the reference regimen is 50 Units across five sites. Those details determine which evidence and assessment interval apply.